GLP-1 menopause weight gain research: 7 Encouraging Findings and Important Limits (2026)

Published research shows that GLP-1 receptor agonist–based treatments can produce substantial average weight reductions in adults with overweight or obesity, including postmenopausal women, but it has not established that menopause itself causes a uniquely strong or weak response. In the randomized STEP 1 trial, semaglutide participants lost an average 14.9% of starting weight versus 2.4% with placebo over 68 weeks; the study was not designed as a menopause-specific trial. The longitudinal SWAN study separately found that fat gain accelerated and lean mass began declining around the menopause transition without a comparable acceleration in total scale-weight gain. These primary sources distinguish evidence of treatment-related weight reduction from evidence about how menopause changes body composition. [1,2]

Table of contents

1. The key question and seven findings
2. What SWAN actually found
3. GLP-1 menopause weight gain research: evidence table
4. What randomized GLP-1 trials establish
5. What menopause-specific analyses can and cannot prove
6. Biological questions beyond the scale
7. Safety, generalizability and regulatory context
8. The next research questions
9. Frequently asked questions
10. References

The key question and seven findings

The most accurate answer to the question behind GLP-1 menopause weight gain research is qualified optimism. Well-designed randomized trials show average weight reduction with particular incretin-based interventions in defined adult populations. Smaller observational studies and post-hoc analyses suggest that clinically relevant responses also occur during and after menopause. Yet very few were designed specifically to test menopause as a modifier of treatment effect.

This article keeps three concepts separate: weight gain over time during midlife, body-composition changes associated with the menopause transition, and weight reduction recorded during trials of obesity treatments. Mixing these concepts can lead to claims that seem intuitive but exceed what a study actually measured. This separation guides GLP-1 menopause weight gain research.

Finding 1: Menopause changes composition, not simply body weight

The Study of Women’s Health Across the Nation (SWAN) followed women through reproductive aging and documented changing patterns of fat and lean tissue. In an analysis by Greendale and colleagues published in JCI Insight in 2019, investigators examined 1,246 women relative to their final menstrual period. They found that fat accumulation accelerated and lean mass began to fall as the transition began. [1]

This finding is central to GLP-1 menopause weight gain research because a scale cannot distinguish fat mass from lean tissue. Two people can register similar total body weights while carrying very different proportions of each. Even when the average rate of weight gain did not increase at transition onset, the underlying compartments changed.

Finding 2: Large GLP-1 trials show effects, not menopause-specific causation

In STEP 1, Wilding and colleagues randomized 1,961 adults without diabetes to semaglutide or placebo with lifestyle intervention. At week 68, mean weight changes were −14.9% and −2.4%, respectively. The original trial established an overall effect for the population studied; it did not determine how the hormone changes of perimenopause altered that effect. [2]

GLP-1 menopause weight gain research should therefore avoid presenting STEP 1’s overall average as an outcome measured exclusively in women passing through menopause. It is a strong randomized estimate for eligible adults, not a direct estimate of the causal interaction between reproductive stage and medication response.

Finding 3: A postmenopausal semaglutide cohort showed an association with hormone therapy

A 2024 Menopause paper by Hurtado Andrade and colleagues reviewed clinical records of postmenopausal women receiving semaglutide. Among 106 women with relevant data, the investigators compared those using menopause hormone therapy with those who were not. Mean total body weight loss at 12 months was 16% in the hormone-therapy group and 12% in the nonuser group. [3]

This is relevant to GLP-1 menopause weight gain research, but it is a retrospective observational association. Patients were not randomized to hormone therapy; groups could differ in characteristics and care patterns. The result does not prove that adding hormone therapy enhances semaglutide’s effect or establish a strategy for an individual consumer.

Finding 4: Response was reported across reproductive stages in tirzepatide trials

Tchang and colleagues published a post-hoc analysis of women enrolled in the SURMOUNT program in Obesity in 2025. In SURMOUNT-1, the reported weight reductions with tirzepatide versus placebo were 26% versus 2% among women classified as premenopausal, 23% versus 3% in perimenopause, and 23% versus 3% after menopause. [4]

Tirzepatide activates both GIP and GLP-1 receptors, so it must not be mislabeled as a selective GLP-1 receptor agonist or treated as pharmacologically identical to semaglutide. GLP-1 menopause weight gain research can discuss it within the broader incretin evidence base only when the mechanism and trial design are clearly distinguished.

Finding 5: A numerical subgroup gap is not proof of a biological difference

The apparent variation among reproductive-stage estimates raises an interesting hypothesis: perhaps physiology across the transition influences response. Yet stages in the published SURMOUNT analysis were assigned retrospectively using age, recorded history and some available clinical information. Such classification is less rigorous than prospectively assessing stage with a standardized protocol.

For GLP-1 menopause weight gain research, a subgroup average alone does not show that menopause changes the treatment effect. Researchers need appropriate interaction testing, uncertainty estimates, attention to multiple comparisons and sufficient statistical power. A result can be statistically different from placebo within multiple subgroups without demonstrating that the subgroups differ from one another.

Finding 6: Weight reduction is not the same as preserving muscle

Weight is an aggregate of fat, lean tissue, bone and other components. The SWAN findings highlight why separating those components matters in midlife. Weight-loss trials may report total kilograms or percentages without adequately describing muscle strength, function, changes in physical activity or long-term body composition across menopausal stages.

Any comprehensive account of GLP-1 menopause weight gain research should therefore ask about more than scale weight. A lower number does not, by itself, answer whether muscle function, visceral fat, metabolic health or everyday functioning improved. Different outcomes require different validated measurements and sometimes separate trials.

Finding 7: Uncertainty should guide better trials

Existing findings provide a foundation for research that deliberately enrolls and characterizes women across reproductive stages. The most useful next step is not extrapolating from one observational association; it is studying whether stage, hormone exposure and body composition systematically modify treatment outcomes with prespecified methods.

The promise of GLP-1 menopause weight gain research is the ability to ask more precise questions about life-stage biology. As the evidence expands, researchers can distinguish effects related to aging, changes in ovarian function, underlying health conditions and treatment exposure, rather than attributing all midlife changes to one cause.

What SWAN actually found

SWAN is important because it tracked natural changes during midlife independently of a GLP-1 intervention. In their 2019 analysis, Greendale and colleagues anchored body-composition trajectories to the final menstrual period instead of assuming that every woman of a particular age was in the same reproductive state. Their dataset included 1,246 participants from multiple racial and ethnic groups. [1]

The researchers reported an annual mean absolute fat-mass increase of approximately 0.25 kg before the transition and 0.45 kg during the transition. Lean mass had been increasing slightly before the transition but began declining once it started. The study estimated a 3.6% cumulative rise in proportion fat mass and a 1.9% cumulative decline in proportion lean mass during a roughly 3.5-year transition interval. [1]

Importantly, the investigators did not identify a comparable acceleration in the rate of total weight gain at the transition’s beginning. Gains in fat and losses in lean tissue offset each other in the total. This is a surprisingly useful distinction in GLP-1 menopause weight gain research, where casual discussions often imply that a sudden increase on the scale is inevitable or uniquely caused by menopause.

SWAN does not show that every individual experiences the same pattern. It presents average trajectories across a diverse longitudinal sample. Personal histories differ in timing, physical activity, medications, chronic disease, social circumstances and health behaviours. As with any observational cohort, its findings describe associations and trajectories rather than randomly assigned hormonal exposure. GLP-1 menopause weight gain research must respect that limit.

Researchers can use SWAN’s lesson to avoid confounding aging with reproductive transition. Both occur together, but they are not interchangeable. A design that merely compares younger and older women risks incorporating age-related differences in lifestyle, health and accumulated exposures that are not direct effects of menopause.

This is why GLP-1 menopause weight gain research should establish what the untreated background trajectory looks like before interpreting drug-related changes. Understanding baseline fat and lean tissue shifts can help select endpoints and identify meaningful subgroup hypotheses without suggesting that menopause alone explains every change.

GLP-1 menopause weight gain research: evidence table

Study and publication	Design / population	Verified quantitative finding	What it cannot establish
SWAN body-composition study, Greendale et al., JCI Insight 2019 [1]	Longitudinal cohort; 1,246 women	Mean fat-mass gain rose from 0.25 to 0.45 kg annually across pretransition and transition periods	Effect of a GLP-1 therapy, because none was assigned
STEP 1, Wilding et al., NEJM 2021 [2]	Randomized trial; 1,961 adults without diabetes	Mean weight change −14.9% with semaglutide vs −2.4% placebo at 68 weeks	A menopause-specific causal response difference
Postmenopausal semaglutide cohort, Hurtado Andrade et al., Menopause 2024 [3]	Retrospective records; 106 women	At 12 months, mean loss 16% with concomitant hormone therapy vs 12% without	Causal benefit of hormone therapy or randomized comparison
SURMOUNT reproductive-stage analysis, Tchang et al., Obesity 2025 [4]	Post-hoc analysis of randomized tirzepatide trials	SURMOUNT-1 estimates: 26% vs 2%, 23% vs 3%, and 23% vs 3% across pre-, peri- and postmenopause	That tirzepatide and semaglutide are interchangeable, or that menopause caused subgroup differences

The table deliberately compares different study types rather than pooling their numbers. A longitudinal natural-history study, a primary randomized treatment trial, an electronic-record review and a post-hoc analysis answer distinct questions. Their percentages are not a direct league table of medications or reproductive-stage effects. Distinguishing designs is essential in GLP-1 menopause weight gain research.

GLP-1 menopause weight gain research becomes misleading when a result from one population is transplanted into another. For example, the semaglutide cohort’s 12-month percentages should not be compared naively with STEP 1’s 68-week overall estimate to infer that menopause hormone therapy explains a difference. Duration, baseline health, selection and analytical methods all differ.

What randomized GLP-1 trials establish

Random assignment helps balance measured and unmeasured participant characteristics across study arms. In STEP 1, adults with obesity or overweight and a related condition were randomized to semaglutide or placebo, alongside lifestyle intervention. The primary publication reported a substantial between-group weight difference over 68 weeks, supporting a treatment effect in that defined population. [2]

The trial is powerful evidence for obesity research, but not every variable within it was randomized. Sex and menopausal stage are characteristics participants brought to the study. To determine whether menopause alters a treatment effect, researchers would need an explicit comparative analysis with appropriate design and statistical controls. That is a key distinction in GLP-1 menopause weight gain research.

A distinction that often disappears from GLP-1 menopause weight gain research is the difference between representation and subgroup proof. Having many women in a major trial improves relevance, but it does not automatically establish efficacy by menopausal stage. A trial may be powered to detect an overall treatment difference and still have insufficient power to detect smaller effect modifications.

Nor does the general STEP 1 result establish an effect on hot flashes, sleep disturbances or every symptom associated with menopause. The study addressed weight outcomes under its protocol. Other questions require their own endpoints and evidence, and an intervention that affects appetite does not necessarily address the entire complex physiology of reproductive aging. GLP-1 menopause weight gain research should not imply otherwise.

For GLP-1 menopause weight gain research, mechanistic plausibility and randomized effectiveness should be considered together without confusing them. GLP-1 receptor activation is associated with appetite and energy-intake regulation. Whether changes in ovarian hormones alter the magnitude of that effect is a distinct question requiring direct testing.

Clinical trials also have eligibility criteria and structured follow-up. Results can differ outside the studied circumstances because participants have different conditions, access to monitoring, patterns of continuation and concurrent treatments. A carefully reported average does not define an expected outcome for an arbitrary individual. This also applies to GLP-1 menopause weight gain research.

What menopause-specific analyses can and cannot prove

The 2024 Mayo Clinic Health System retrospective study is especially relevant because it examined postmenopausal women actually receiving semaglutide. The investigators compared hormone-therapy users and nonusers through medical records and reported higher average weight loss among hormone-therapy users at several measurement points. [3]

The paper’s reported averages were 7% versus 5% at three months, 13% versus 9% at six months, 15% versus 10% at nine months, and 16% versus 12% at twelve months for hormone-therapy users versus nonusers. These are published observational group estimates, not results of randomly allocating hormone therapy. The sample and differences in baseline characteristics limit causal interpretation. [3]

GLP-1 menopause weight gain research should not translate that association into consumer instructions. Hormone therapy may correlate with healthcare engagement, symptom burden, access, baseline characteristics or other factors. Even statistical adjustment cannot remove all possible unmeasured confounding from retrospective records.

The Tchang and colleagues analysis offers a complementary angle. It used trial data from tirzepatide studies and classified women by reproductive stage after enrollment. The SURMOUNT-1 comparisons against placebo were large across all three reported stages. However, randomized drug allocation does not mean menopause stage was randomized. [4]

The SURMOUNT analysis is particularly useful for GLP-1 menopause weight gain research because it shows that reported weight reductions were not confined to younger women. But its results should be described as data from a dual GIP/GLP-1 receptor agonist, and its stage classification should be visible in every interpretation.

There are two different possible claims. The first is that a treatment group had greater average weight reduction than placebo within women classified as postmenopausal. The second is that postmenopausal status caused the treatment to work differently than it did before menopause. The first can be evaluated in subgroup data; the second demands careful interaction and causal reasoning. This distinction protects GLP-1 menopause weight gain research from overstatement.

For clarity, GLP-1 menopause weight gain research currently offers stronger evidence for the presence of weight-loss effects in studied women than for a definitive ranking of responses across reproductive stages. The distinction is a sign of scientific precision, not skepticism about the observed treatment differences.

Why pooled percentages are tempting but hazardous

A reader could calculate differences between numbers from several publications and conclude that one therapy is superior for menopause-related weight gain. Such arithmetic would ignore treatment mechanisms, trial durations, participant definitions, missing-data rules, baseline weight and background interventions. Cross-trial subtraction is not a randomized head-to-head comparison.

This pitfall matters in GLP-1 menopause weight gain research because the field is developing quickly and summaries often compress several studies into one headline. Better reporting preserves each study’s population and original endpoint, acknowledges uncertainty and avoids claiming superiority without an appropriate comparative design.

Biological questions beyond the scale

The menopause transition involves shifts in ovarian hormones, sleep patterns, body-fat distribution and other processes. These may intersect with appetite regulation and metabolic health. But a plausible biological pathway is not evidence that the pathway explains a particular drug-response estimate in a particular subgroup. Mechanistic questions remain open in GLP-1 menopause weight gain research.

Body composition is arguably the most important missing piece in many summaries of GLP-1 menopause weight gain research. SWAN documented changes in fat and lean tissue, so an endpoint that looks only at overall weight may miss whether the intervention changes the balance between compartments.

Direct measurements such as validated imaging or dual-energy X-ray absorptiometry can help characterize fat and lean mass. Measures of strength, mobility or physical performance answer functional questions that body weight cannot. Laboratory biomarkers and cardiovascular endpoints require separate interpretation. A positive result in one domain should not be automatically promoted to every other domain. These measurements could enrich GLP-1 menopause weight gain research.

The distribution of abdominal fat is another area worth investigating. Increased central adiposity can accompany reproductive aging, but waist measurements and imaging quantify different aspects. A change in waist circumference does not necessarily reveal the quantity of visceral tissue or predict an individual’s future cardiovascular events without additional evidence.

One question for GLP-1 menopause weight gain research is whether the proportion of weight lost from fat versus lean tissue varies across stages. Another is whether prior body composition, rather than reproductive stage itself, explains some differences in reported response. Both questions could be addressed with prespecified imaging and functional assessments. Robust body-composition data would strengthen GLP-1 menopause weight gain research.

Researchers should also examine the effects of sleep disturbance, medications, diet quality and physical activity as possible correlates or modifiers, but without turning observational findings into prescriptive claims. Menopause is one important context in a much broader network of determinants of weight and health.

Safety, generalizability and regulatory context

Safety needs a place beside average weight outcomes. In the STEP 1 publication, gastrointestinal disorders were commonly reported with semaglutide and were often transient. The study also reported discontinuations related to adverse events. These outcomes remind readers that a favourable mean efficacy result does not make an intervention appropriate or tolerable for everyone. [2]

For GLP-1 menopause weight gain research, a subgroup’s average weight change is not a comprehensive subgroup safety analysis. Menopause-specific investigations should report adverse events, discontinuation, follow-up and missing data within each relevant group when the design permits. Otherwise, readers may mistakenly attach a trial-wide tolerability result to a smaller subgroup.

The retrospective hormone-therapy association does not prove that using hormones together with semaglutide is universally safe, beneficial or indicated. Similarly, positive results in a tirzepatide reproductive-stage analysis cannot substitute for semaglutide-specific trial findings. Different molecules have different pharmacology and clinical evidence. GLP-1 menopause weight gain research must keep each agent distinct.

Regulatory status also differs by product, indication and jurisdiction. A research article must not imply that every GLP-1-related compound is approved for every weight or menopause indication. Nor should research outcomes be presented as a recommendation for consumer use. This article is an evaluation of evidence rather than individual medical guidance.

Another boundary concerns diabetes. STEP 1 studied adults without diabetes, while other metabolic trials enroll different populations. Differences in baseline glucose regulation, concomitant medications and eligibility may influence observed outcomes. GLP-1 menopause weight gain research should identify the studied population each time it gives a quantitative estimate.

Even the word “menopause” requires care. Natural menopause, medically induced menopause, perimenopause and postmenopause are not synonymous. Investigators may use age-based proxies, clinical history or biochemical markers, each with limitations. Without harmonized definitions, comparisons across studies can create an artificial appearance of consensus. Standardization is needed in GLP-1 menopause weight gain research.

The next research questions

First, studies should prospectively classify reproductive stage. SWAN showed the value of anchoring natural-history changes to the final menstrual period. Intervention studies could combine established staging methods with repeated symptom and hormonal measurements where scientifically appropriate, recognizing that no single measure fully describes an individual’s biology.

Second, GLP-1 menopause weight gain research would benefit from prespecified tests of whether treatment effects differ by stage, rather than informal comparisons of subgroup means. Those analyses should report interaction estimates, confidence intervals, the number of participants in each category and a plan for controlling multiple comparisons.

Third, investigators should examine hormone-therapy exposure without assuming causation from the Mayo Clinic retrospective association. A carefully designed study could document timing, indication, duration and potential confounders. It would need appropriate ethical and methodological safeguards before attributing a response difference to hormone therapy itself.

Fourth, future trials should measure body composition and physical function together. Total mass loss is an informative endpoint, but strength, lean tissue and regional adiposity would help determine which changes matter for women during aging. A prespecified framework would reduce the temptation to highlight whichever outcome appears most impressive afterward.

Fifth, longer follow-up could examine persistence of weight and composition changes, including what happens when trial exposure ends or changes. The primary trial average is a snapshot over a defined follow-up period. It does not settle every question about maintenance over years or how outcomes vary with treatment interruption.

Sixth, GLP-1 menopause weight gain research needs diversity in geography, racial and ethnic background, socioeconomic circumstances and pre-existing health conditions. SWAN’s diverse cohort was valuable for describing heterogeneous midlife patterns, and intervention studies should be similarly transparent about whom their findings represent.

Seventh, researchers should report patient-relevant outcomes without collapsing them into a single measure of body mass. Well-being, symptoms, physical capability and adverse effects require direct evaluation. Scientific optimism is most useful when it is joined to precise endpoints and honest explanations of uncertainty.

In summary, GLP-1 menopause weight gain research supports a hopeful but bounded conclusion: effective weight reduction has been demonstrated in randomized adult obesity trials, and published analyses document responses among women around and after menopause. The claim that menopause itself changes a specific treatment’s effect remains a question for stronger prospective research.

Frequently asked questions

1. Does menopause always cause a sudden increase in body weight?

No. SWAN reported that fat gain accelerated while lean mass declined around the menopause transition, without a detectable acceleration in the overall rate of weight gain at transition onset. That distinction is fundamental to GLP-1 menopause weight gain research, because body composition and scale weight are not interchangeable. [1]

2. Did the STEP 1 trial specifically study women with menopause-related weight gain?

No. STEP 1 randomized 1,961 adults without diabetes and reported mean weight changes of −14.9% with semaglutide and −2.4% with placebo after 68 weeks. It was not designed to isolate menopause-related weight gain or prove menopause-specific treatment effects. [2]

3. Does hormone therapy improve semaglutide-related weight loss?

A retrospective 2024 study found an association: postmenopausal hormone-therapy users receiving semaglutide had higher average weight loss than nonusers. The observation does not establish causation because hormone therapy was not randomly assigned. GLP-1 menopause weight gain research therefore cannot treat the association as proof of an added therapeutic effect. [3]

4. Do published studies show weight reduction after menopause?

Yes. Published semaglutide observational data and a post-hoc tirzepatide analysis report weight reductions among postmenopausal women. However, tirzepatide is a dual GIP/GLP-1 receptor agonist, and none of these subgroup results alone proves that reproductive stage caused a different response. [3,4]

5. What remains unknown about GLP-1 research around menopause?

Important questions include the effect of prospectively defined menopausal stage, differences in fat and lean mass, physical function, safety by subgroup and long-term maintenance. GLP-1 menopause weight gain research needs trials that plan these comparisons in advance and report complete uncertainty estimates.

References

1. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. https://doi.org/10.1172/jci.insight.124865
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Hurtado Andrade MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266–274. https://doi.org/10.1097/GME.0000000000002310
4. Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025;33(5):851–860. https://doi.org/10.1002/oby.24254

For laboratory research use only. Not for human consumption.